Immuno-Oncology Market Size Worth USD 216.34 Billion by 2034 | CAGR: 15.2%

The Immuno-oncology market size is expected to reach USD 216.34 billion by 2034, according to a new study by Polaris Market Research. The report “Immuno-Oncology Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body’s immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market’s evolution.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.

Top of FormImmuno-Oncology Market Report Highlights

• In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.
• Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.
• In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.
• The Asia Pacific Immuno-Oncology Market would report a CAGR of  16.3% by 2034, fueled by rising treatment access and healthcare investments.
• A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.

Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:

By Treatment Approaches Outlook (Revenue, USD Billion, 2020–2034)

• Monoclonal Antibodies
• Therapeutic Vaccines
• Checkpoint Inhibitors
• Cytokines

By Novel Target Type Outlook (Revenue, USD Billion, 2020–2034)

• IDO1i
• LAG-3 CPI
• Oncolytic Virus
• STING Agonist
• TLR Agonist
• HDACi
• TIL
• VEGFi
• MEKi
• TIGIT
• CPI
• GITR Agonist
• TGF-b trap
• A2AR Antagonist/CD73i

By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020–2034)

• Melanoma
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma
• Head, Face & Neck Cancer
• Bladder Cancer
• Classical Hodgkin’s Lymphoma
• Merkel Cell Carcinoma
• Other Cancer Types

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa